

<p>Curriculum Vitae</p> 	
<p>Personal information First name / Surname Address Telephone, Email Nationality Date of birth Gender</p>	<p>SALVATORE ANNUNZIATA salvatore.annunziata@policlinicogemelli.it Italian Male</p>
<p>Education Dates Title Dates Title Dates Title Dates Title Dates Title</p>	<p>January 2021 – January 2031 Qualification as Full Professor in Nuclear Medicine MIUR July 2020 – July 2029 Qualification as Associate Professor in Nuclear Medicine MIUR November 2017- May 2021 PhD in Oncological Science Università Cattolica del Sacro Cuore, Rome, Italy July 2012 – June 2017 Specialty in Nuclear Medicine Università Cattolica del Sacro Cuore, Policlinico A. Gemelli, Rome, Italy September 2005 – October 2011 Degree in Medicine and Surgery Università Cattolica del Sacro Cuore, Rome, Italy</p>
<p>Fellowships Dates Dates</p>	<p>November 2016 Memorial Sloan Kettering Cancer Center, New York, USA, Nuclear Medicine Unit, Observer in PET/CT and radionuclide therapy in oncology December 2016 Ichan - Mount Sinai Hospital, New York, USA, Nuclear Medicine Unit Observer in PET/CT and PET/MR in lymphoma</p>
<p>Mother tongue Other language</p>	<p>Italian Good knowledge of English (writing, reading and speaking)</p>

<p>Work Experience</p>	<p>Dates February 2021 – now Nuclear Physician, Head GSTeP Radiopharmacy, TOC Coordinator Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma</p> <p>Dates June 2018 – January 2021 Nuclear Physician, PET/CT IRCCS Istituto Nazionale dei Tumori Regina Elena (IRE), Roma</p> <p>Dates October 2017 – October 2020 Nuclear Cardiology Physician Istituto Diagnostico Meduri, Reggio Calabria</p>
<p>Scientific Boards</p> <p>Scientific Presentations</p> <p>Scientific Interests</p> <p>Ongoing Clinical Trials</p> <p>Ongoing Grants</p>	<p>Theranostic Oncology Center, Fondazione Policlinico Gemelli, 2025- Congress Board, European Association Nuclear Medicine (EANM), 2020-2024 Radiopharma Group Head, Italian Association Nuclear Medicine (AIMN), 2023- EU Commission, SAMIRA-ERVI, Italian MOH delegate, 2023- Tracer Working Group, European Association Translational Research (EATRIS) Congress Board, Italian Association Nuclear Medicine (AIMN), 2017 Young Committee, Italian Association Nuclear Medicine (AIMN), 2017-2022 Commissione Imaging, Rete Lazio, Federazione Italiana Linfomi (FIL), 2023-</p> <p>Invited speaker at EANM Congress 2019-2025 Invited speaker at AIMN Congress 2015, 2017, 2024 Invited speaker at European Congress of Cardio-Thoracic Surgery 2016 Speaker at International Workshop on PET in Lymphoma 2014, 2016</p> <p>Nuclear Medicine - PET/CT – Radiopharmacy – Theranostics</p> <p>Site PI. Profit PTF301. A pivotal phase 3 clinical trial to assess the diagnostic performance and safety of [68Ga]Ga-PentixaFor in lymphoma. PI. Grant. Finalizzata Giovani Ricercatori, GR-2019-12370372, MOH, PET radiomics for personalised medicine in high-grade lymphoma. Facility Head. Grant. PNRR 2023, MOH, 18F-FAPI in lung fibrosis. Facility Head. Grant. Finalizzata GR-2021. 18F-MCC225 in depression. Facility Head. Profit, CAAA617D12302. PSMA-DC: 177Lu-PSMA-617. Co-PI. Grant. Bando Veronesi 2022. PSMA PET Radiomics. Collaborator of Profit: EuroNET PHL C2, MCL0208, MK-3475-C11.</p> <p>Scientific Coordinator, IHI Horizon, Thera4Care, Theranostic Ecosystem for Personalised Care, global 24M eur, local 2M eur, 2024-2029 PI, Finalizzata, MOH, GR-2019-12370372, PET radiomics in high-grade lymphoma. 449k eur, 2021-2025. Site PI. Profit PTF301. A pivotal phase 3 clinical trial to assess the diagnostic performance and safety of 68Ga-PentixaFor in lymphoma. 200k eur, 2024-2025 Site PI. EU4H-2023-PJ-05, CLAUD-IT. Implementing clinical audits in Europe – a practical and multidisciplinary approach, global 1M eur, local 100k, 2024-2027 Site PI. EU4H-2023-PJ-05, PRISMA-SAMIRA. Preparatory activities to support Implementation of quality and Safety of Medical ionising radiation Applications, global 1.2M eur, local 50k, 2024-2025 Facility Head, Finalizzata GR-2021. 18F-MCC225 in depression. 440k eur, 2024 Facility Head, PNRR, MOH, 18F-FAPI in lung fibrosis. 240k eur, 2024-2027 Facility Head, PRIN, MUR, 68Ga-Exendine in diabetes. 240k eur, 2024-2027</p>

<p>Awards</p>	<ul style="list-style-type: none"> - March 2019, Ones to Watch award, Society of Nuclear Medicine and Molecular Imaging (SNMMI), Among 30 best young SNMMI members. - July 2016, Young Investigator Meeting, European Society of Nuclear Medicine and Molecular Imaging (EANM), <i>xSPECT analysis in patients with Paget disease of the bone.</i> - July 2014, Young Investigator Meeting, European Society of Nuclear Medicine and Molecular Imaging (EANM), <i>The predictive value of microRNAs (miRNAs) in the assessment of response to radioiodine therapy (RAI) in patients with differentiated thyroid carcinoma.</i>
<p>Teaching activities</p>	<ul style="list-style-type: none"> - Guest Lecturer, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Surveys ed Evidence Based Medicine in Nuclear Medicine (2022-23) - Teacher, EU Erasmus+ School, Radioligand Therapy Academy (2024) - Teacher, Master course, Ricercatore IRCCS, ALTEMS Unicatt (2024-2025) - Teacher, Master course, Gestione dei Radiofarmaci, Università di Salerno (2024) - Teacher, Webinar, AIMN, Nuclear Medicine for Zoomers (13.03.2024) - Teacher, Webinar, AIRO, Radiomics in PET/CT (12.04.24) - Teacher, European School of Multimodality Imaging and Therapy (ESMIT) on Malignant versus benign bone tumors: a 10-point guide to survival (21.05.2021) - Teacher ECM, Società Italiana di Farmacia Ospedaliera, Napoli (11.2024) - Teacher ECM, Ospedale Pediatrico Bambin Gesù, Roma (11.2024) - Teacher ECM, European School of Multimodality Imaging and Therapy (ESMIT) on PET/CT in lymphoma methodological aspects (02.07.2018) - Teacher ECM, Associazione Italiana di Medicina Nucleare (AIMN) on Nuclear Medicine in Thyroid Cancer (05.03.2017)

Scientific publications
(>100 papers, Scopus H-Index 24)

Original Papers as main author

Triumbari EK, Boldrini L, Hohaus S. ... *Annunziata S*. The predictive power of 18F-FDG PET/CT two-lesions radiomics and conventional models in classical Hodgkin's Lymphoma: a comparative retrospectively-validated study. *Ann Hematol*. 2025 Jan;104(1):641-651.

Maccora D, Leccisotti L., Hohaus S. ... *Annunziata S*. The Predictive Role of Baseline 18F-FDG PET/CT Radiomics in Follicular Lymphoma on Watchful Waiting: A Preliminary Study. *Diagnostics (Basel)*. 2025 Feb 11;15(4):432.

Rizzo A, Treglia G, ... *Annunziata S*. Diagnostic performance of [18 F]FDG PET/CT in patients with Kaposi sarcoma: an Italian monocentric retrospective study. *Clin Transl Imaging* 13, 167–175 (2025).

Pizzuto DA, Guerreri M, ... Boldrini L, *Annunziata S*. The clinical predictive value of radiomic features from [68Ga]GaPSMA-11 and [18F]F-PSMA-1007 PET in patients with prostate cancer: a preliminary comparative study. *Clinical and Translational Imaging* (2024) 12:629–638

Annunziata S, Testart N, Auf der Springe K, Cuzzocrea M, Nicod Lalonde M, Schaefer N, Prior JO, Garibotto V, Treglia G. Contrast enhanced CT on PET/CT imaging in clinical routine: an international survey. *Front Med (Lausanne)*. 2023 Oct 16;10:1290956.

Triumbari EKA, Gatta R, Maiolo E, ..., Hohaus S, Nardo L, Morland D, *Annunziata S*. Baseline 18F-FDG PET/CT Radiomics in Classical Hodgkin's Lymphoma: The Predictive Role of the Largest and the Hottest Lesions. *Diagnostics (Basel)*. 2023 Apr 11;13(8):1391.

Triumbari EKA, Morland D, ..., *Annunziata S*. Classical Hodgkin Lymphoma: A Joint Clinical and PET Model to Predict Poor Responders at Interim Assessment. *Diagnostics (Basel)*. 2022 Sep 26;12(10):2325.

Pizzuto DA, Triumbari EKA, ... Totaro A. *Annunziata S*. 18F-Fluoroethylcholine PET/CT Radiomic Analysis for Prostate Cancer Patients: A Monocentric Study. *Int J Mol Sci*. 2022 Aug 14;23(16):9120.

Morland D, Triumbari EKA, ..., *Annunziata S*. Healthy Organs Uptake on Baseline 18F-FDG PET/CT as an Alternative to Total Metabolic Tumor Volume to Predict Event-Free Survival in Classical Hodgkin's Lymphoma. *Front Med (Lausanne)*. 2022 Jun 22;9:913866.

Annunziata S, Pelliccioni A, Maiolo E et al. The prognostic role of FDG-PET/CT at the end of treatment in DLBCL: a pilot study application of NN to predict time-to-event. *Ann Nucl Med*. 2021; Jan 35:1:102-110

Annunziata S, Bauckneht M, Albano D et al. Impact of the COVID-19 pandemic in Nuclear Medicine departments: preliminary report of the first international survey. *Eur J Nucl Med Mol Imaging*. 2020 Aug;47(9):2090-2099.

Albano D, Laudicella R, ... Bauckneht M, *Annunziata S*. Young Italian Association of Nuclear Medicine. The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study. *Cancers (Basel)*. 2019 Nov 21;11(12).

Annunziata S, Cuccaro A, Tisi MC, et al. FDG-PET/CT at the end of Immune-chemotherapy in Follicular Lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). *Ann Nucl Med*. 2018 Jun;32(5):372-377.

Annunziata S, Cuccaro A, Calcagni M. FDG-PET/CT in Hodgkin Lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). *Ann Nucl Med*. 2016 Oct;30(8):588-92.

Other Original Papers

Pirosa MC, ... *Annunziata S*, Hohaus S, Rossi D. A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNA. *Blood*. 2025 May 13;blood.2024027355.

Florit A, ... *Annunziata S*, de Geus-Oei LF, Sala E, Scambia G, Rufini V, van Velden FHP, Collarino A. An exploratory assessment of early and delta PET radiomic features for outcome prediction in locally advanced cervical cancer. *Eur J Nucl Med Mol Imaging*. 2025 Jun 18

Galli E, Leccisotti L, *Annunziata S*... Hohaus S, Baseline Tumor Burden Assessed With AI-Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR-T in Aggressive B-Cell Lymphoma. *Hematol Oncol*. 2025 Jan;43(1):e70029.

Pizzuto DA, Lococo F, *Annunziata S* ... Mendogni P. The Role of [18F]F-FDG PET/CT for Predicting Histology and Prognosis in Patients with Thymic Lesions. *Mol Diagn Ther*. 2025 Mar;29(2):239-248

Collarino A, Feudo V, *Annunziata S*, ... Sala E, Rufini V, van Velden FH. Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in Locally Advanced Cervical Cancer? *J Nucl Med*. 2024 Mar 28;jnumed.123.267044.

Bellisario F, Attili F, Campana F, ..., *Annunziata S*, D'Alò F, Hohaus S. Endoscopic Ultrasound-Guided Fine Needle Biopsy in the Diagnostic Work-Up of Deep-Seated Lymphadenopathies and Spleen Lesions: A Monocentric Experience. *Diagnostics (Basel)*. 2023 Sep 1;13(17):2839.

Pecce V, Sponziello M, Verrienti A, Grani G, Abballe L, Bini S, *Annunziata S*, Perotti G, Salvatori M, Zagaria L, Maggisano V, Russo D, Filetti S, Durante C. The role of miR-139-5p in radioiodine-resistant thyroid cancer. *J Endocrinol Invest*. 2023 Oct;46(10):2079-2093.

Milano A, Capotosti A, ... *Annunziata S*, Iezzi R, Indovina L. Dose-response Analysis in Hepatic Tumors Treated with 90Y-TARE According to a Personalized Dosimetric Workflow: Preliminary Results. *Curr Radiopharm*. 2023;16(4):326-336.

Maccora D, ... *Annunziata S*, Bruno I. Comparison between MIBI-based radiopharmaceuticals for parathyroid scintigraphy: quantitative evaluation and correlation with clinical-laboratory parameters. *J Endocrinol Invest*. 2022 Nov;45(11):2139-2147.

Leccisotti L, Maccora D, ..., *Annunziata S*, Rufini V, Giordano A, Hohaus S. Predicting time to treatment in follicular lymphoma on watchful waiting using baseline metabolic tumour burden. *J Cancer Res Clin Oncol*. 2023 Jul;149(7):2783-2791.

	<p>Morland D, Chiappetta M, Falcoz PE, Chenard MP, <i>Annunziata S</i>, Boldrini L, Lococo F, Imperiale A. 18F-FDG primary tumor uptake to improve N status prediction in cT1 non-metastatic non-small cell lung cancer: development and validation of a positron emission tomography model. <i>Front Med (Lausanne)</i>. 2023 Apr 26;10:1141636.</p> <p>Capotosti A, Moretti R, Milano A, Nardini M, Cusumano D, <i>Annunziata S</i>, Capogni M, D'Arienzo M, Placidi L, Indovina L. Up-to-Date Optimization of the 90Y-PET/CT Reconstruction Protocol for Volumetric Quantification in Trans-Arterial RadioEmbolization (TARE) Procedures in the Era of Theranostics. <i>Applied Sciences</i>. 2022; 12(17):8418.</p> <p>Cuccaro A, Bellesi S, <i>Annunziata S</i>, et al. PD-L1 expression in peripheral blood granulocytes at diagnosis as prognostic factor in classical Hodgkin lymphoma. <i>J Leukoc Biol</i>. 2022 Jan 20.</p> <p>Spina V, Brusca A, <i>Annunziata S</i>, Rossi D et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. <i>Blood</i>. 2018 May 31;131(22):2413-2425.</p> <p>Evangelista L, Cuocolo A, <i>Annunziata S</i>, et al. Performance of FDG-PET/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial. <i>Eur J Nucl Med Mol Imaging</i>. 2018 Oct;45(11):1898-1907</p> <p>Cuccaro A, <i>Annunziata S</i>, et al. CD68+ Cell Count, Early Evaluation with PET and Plasma TARC Levels Predict Response In Hodgkin Lymphoma. <i>Cancer Med</i>. 2016;5(3):398-406.</p> <p>Pizzuto DA, <i>Annunziata S</i>, Ieria FP, et al. Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer. <i>Q J Nucl Med Mol Imaging</i>. 2018 Jan 17</p>
Meta-analyses as main author	<p><i>Annunziata S</i>, Pizzuto DA, Caldarella C, et al. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in gallbladder cancer: A meta-analysis. <i>World J Gastroenterol</i>. 2015 Oct 28;21(40):11481-8.</p> <p><i>Annunziata S</i>, Caldarella C, Treglia G. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma: a meta-analysis. <i>Biomed Res Int</i>. 2014;2014:247693.</p>
Other Meta-analyses	<p>Florit A, Fendler W, <i>Annunziata S</i>, ... Collarino A. Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [18F]FDG in gynaecological malignancies: systematic literature review and meta-analysis. <i>Eur J Nucl Med Mol Imaging</i>. 2025 Apr 25.</p> <p>Rizzo A, Miceli A, ... <i>Annunziata S</i>, Treglia G. Diagnostic Accuracy of [68Ga]Ga Labeled Fibroblast-Activation Protein Inhibitors in Detecting Head and Neck Cancer Lesions Using Positron Emission Tomography: A Systematic Review and a Meta-Analysis. <i>Pharmaceuticals (Basel)</i>. 2023 Nov 30;16(12):1664.</p> <p>Rizzo A, Racca M, ...<i>Annunziata S</i>, Treglia G. Diagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis. <i>Int J Mol Sci</i>. 2023 Jun 14;24(12):10136.</p> <p>Rizzo A,...<i>Annunziata S</i>, Treglia G. Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis. <i>Pharmaceuticals (Basel)</i>. 2022 Nov 8;15(11):1368.</p> <p>Bauckneht. M, <i>Annunziata S</i> et al. Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis. <i>Diagnostics (Basel)</i>. 2020 Aug 16;10(8):598</p> <p>Treglia G, <i>Annunziata S</i>, Pizzuto DA, et al. Detection Rate of (18)F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis. <i>Cancers (Basel)</i>. 2019 May 23;11(5)</p> <p>Treglia G, <i>Annunziata S</i>, Sobic Saranovic D, et al. The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review. <i>Acad Radiol</i>. 2014 May;21(5):675-84.</p> <p>Treglia G, Sadeghi R, <i>Annunziata S</i> et al. Diagnostic Accuracy of (18)F-FDG-PET and PET/CT in the Differential Diagnosis between Malignant and Benign Pleural Lesions: A Systematic Review and Meta-Analysis. <i>Acad Radiol</i>. 2014 Jan;21(1):11-20.</p> <p>Treglia G, Sadeghi R, <i>Annunziata S</i>, et al. Diagnostic performance of Fluorine-18-Fluorodeoxyglucose positron emission tomography in the assessment of pleural abnormalities in cancer patients: A systematic review and a meta-analysis. <i>Lung Cancer</i>. 2014 Jan;83(1):1-7.</p> <p>Treglia G, Sadeghi R, <i>Annunziata S</i>, et al. Diagnostic performance of Fluorine-18-Fluorodeoxyglucose positron emission tomography for the diagnosis of osteomyelitis related to diabetic foot: a systematic review and a meta-analysis. <i>Foot (Edinb)</i>. 2013 Dec;23(4)</p> <p>Caldarella C, <i>Annunziata S</i>, Treglia G, et al. Diagnostic performance of positron emission tomography/computed tomography using fluorine-18 fluorodeoxyglucose in detecting loco-regional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis. <i>ScientificWorldJournal</i>. 2014 Feb 4;2014:196068.</p> <p>Treglia G, Sadeghi R, <i>Annunziata S</i>, et al. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the post-chemotherapy management of patients with seminoma: systematic review and meta-analysis. <i>Biomed Res Int</i>. 2014;2014:852681.</p>
Reviews as main author	<p>Albano D, Pizzuto DA... <i>Annunziata S</i>. Semiquantitative 2-[18F]FDG PET/CT-based parameters role in lymphoma. <i>Front Med (Lausanne)</i>. 2024 Dec 18;11:1515040.</p> <p>Galiandro F, Scaldaferrri F, ...Tondolo V, <i>Annunziata S</i>. PET in inflammatory bowel diseases: a new FAPI era? <i>Clinical and Translational Imaging (2024)</i> 12:563–565.</p>

Other Reviews

- Pizzuto, D.A., Calandriello, L., De Martino, I... *Annunziata S.* Positron emission tomography/magnetic resonance in musculoskeletal disorders: proper sequences and workflow optimization. *Clin Transl Imaging* (2024).
- Triumbari EKA, Morland D, ... *Annunziata S.* Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review. *Cancers (Basel)*. 2022 Jul 18;14(14):3488.
- Rizzo A, .. Racca M, *Annunziata S.* PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor? *Cancers (Basel)*. 2022 Aug 21;14(16):4039.
- Morland D, Triumbari EKA, ... Pizzuto D, *Annunziata S.* Radiomics in Oncological PET Imaging: A Systematic Review-Part 1, Supradiaphragmatic Cancers. *Diagnostics (Basel)*. 2022 May 27;12(6):1329.
- Morland D, Triumbari EKA, ... Pizzuto D, *Annunziata S.* Radiomics in Oncological PET Imaging: A Systematic Review-Part 2, Infradiaphragmatic Cancers, Blood Malignancies, Melanoma and Musculoskeletal Cancers. *Diagnostics (Basel)*. 2022 May 27;12(6):1330.
- Annunziata S,* Panagiotidis E. Hybrid positron emission tomography/magnetic resonance imaging in musculoskeletal conditions: be hybrid! *Q J Nucl Med Mol Imaging*. 2022;66(1)
- Annunziata S,* Treglia G, ... Glaudemans AWJM. Nuclear medicine practice in the field of infection and inflammation imaging: a pragmatical survey. *Eur J Nucl Med Mol Imaging*. 2022 Jun;49(7):2113-2119.
- Rizzo A, Triumbari EKA, *Annunziata S.* The role of 18F-FDG PET/CT radiomics in lymphoma. *Clin Transl Imaging* 9, 589–598 (2021)
- Lo Re M, Parente F, *Annunziata S.* Economic networks in the complexity of COVID-19 emergency. A qualitative approach for an actor-network model. in "L'industria, Rivista di economia e politica industriale" 1/2021, pp. 27-42
- Annunziata S* et al. Surveys on COVID in Nuclear Medicine: what happened and what we learned. *Clin Transl Imaging*. 2020;8(5):303-305.
- Annunziata S,* Delgado Bolton R, Treglia G et al. Role of 2-[18F]FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review. *Pharmaceuticals (Basel)*. 2020 Nov 10;13(11):377
- Annunziata S,* Pizzuto DA and Treglia G. Diagnostic Performance of PET Imaging Using Different Radiopharmaceuticals in Prostate Cancer According to Published Meta-Analyses. *Cancers (Basel)*. 2020 Aug 4;12(8):2153.
- Annunziata S,* Laudicella R, Caobelli F, et al. Clinical Value of PET/CT in Staging Melanoma and Potential New Radiotracers. *Current Radiopharm*. 2020;13(1):6-13
- Annunziata S,* Caldarella C, Treglia G. Cost-effectiveness of Fluorine-18-Fluorodeoxyglucose positron emission tomography in tumours other than lung cancer: A systematic review. *World J Radiol*. 2014 Mar 28;6(3):48-55.
- Annunziata S,* Treglia G, Caldarella C, Galiandro F. The role of 18F-FDG-PET and PET/CT in patients with colorectal liver metastases undergoing selective internal radiation therapy with yttrium-90: a first evidence-based review. *ScientificWorldJournal*. 2014 Feb 2;2014:879469.
- Annunziata S,* Giordano A. Authorship problems in scientific literature and in nuclear medicine: the point of view of the young researcher. *Eur J Nucl Med Mol Imaging*. 2014 Jun;41(6):1251-4.
- Cina C, Galiandro F, *Annunziata S...* Rosa F. The role of nuclear medicine imaging in non-oncological surgical emergencies. *Clin Transl Imaging* 13, 17–23 (2025).
- Triumbari EK, Pizzuto DA, ... *Annunziata S,* Di Giuda D. Assessment of dopaminergic pathways in Huntington's Disease: when, how, why? A (clinician-friendly) systematic review of the literature on PET and SPECT applications. *Clinical and Translational Imaging* (2024) 12:755–767
- Rizzo A, Albano D, ... *Annunziata S,* Treglia G. The Potential Role of PSMA-Targeted PET in Salivary Gland Malignancies: An Updated Systematic Review. *Diagnostics (Basel)*. 2024 Jul 14;14(14):1516.
- Rizzo A, Albano D, ... *Annunziata S,* Racca M, Bertagna F, Piccardo A, Treglia G. Diagnostic yield of FAP-guided positron emission tomography in thyroid cancer: a systematic review. *Front Med (Lausanne)*. 2024 Mar 25;11:1381863.
- De Summa, M., Ruggiero, M.R., Spinosa, S., *Annunziata S,* ... Pizzuto DA. Denoising approaches by SubtlePET™ artificial intelligence in positron emission tomography (PET) for clinical routine application. *Clin Transl Imaging* (2024).
- Pizzuto, D.A., Calandriello, L., De Martino, I... *Annunziata S.* Positron emission tomography/magnetic resonance in musculoskeletal disorders: proper sequences and workflow optimization. *Clin Transl Imaging* (2024).
- Moretti R, Meffe G, *Annunziata S,* Capotosti A. Innovations in imaging modalities: a comparative review of MRI, long-axial field-of-view PET, and full-ring CZT-SPECT in detecting bone metastases. *Q J Nucl Med Mol Imaging*. 2023 Dec;67(4):259-270.
- Morland D, Laures N, Triumbari EKA, Perrier M, Imperiale A, *Annunziata S,* Rufini V. Impact of Cold Somatostatin Analog Administration on Somatostatin Receptor Imaging: A Systematic Review. *Clin Nucl Med*. 2023 Jun 1;48(6):467-473.
- Albano D, Treglia G, Dondi F, Calabrò A, Rizzo A, *Annunziata S,* Guerra L, Morbelli S, Tucci A, Bertagna F. 18F-FDG PET/CT Maximum Tumor Dissemination (Dmax) in Lymphoma: A New Prognostic Factor? *Cancers (Basel)*. 2023 Apr 26;15(9):2494.
- Rizzo A, Racca M, ..., *Annunziata S,* Treglia G. Potential Role of PSMA-Targeted PET in Thyroid Malignant Disease: A Systematic Review. *Diagnostics*. 2023 Feb 3;13(3):564.
- Rizzo A, Racca M, ..., *Annunziata S,* Treglia G. The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review. *Cancers (Basel)*. 2023 Jan 5;15(2):355.
- Chiappetta M, Mendogni P, *Annunziata S,* Margaritora S, Lococo F. Is PET/CT Able to Predict Histology in Thymic Epithelial Tumours? A Narrative Review. *Diagnostics (Basel)*. 2022 Dec 29;13(1):98.
- Martinino A, ... *Annunziata S,* Giovanazzo F. Artificial Intelligence in the Diagnosis of Hepatocellular Carcinoma: A Systematic Review. *J Clin Med*. 2022 Oct 28;11(21):6368.

	<p>Gavriilidis P, ... Annunziata S, Wierts R. Positron Range Corrections and Denoising Techniques for Gallium-68 PET Imaging: A Literature Review. <i>Diagnostics</i> (Basel). 2022 Sep 27;12(10):2335.</p> <p>Muoio B, Albano D, Annunziata S, Treglia G. Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis. <i>Diagnostics</i> (Basel). 2022 Jul 8;12(7):1665.</p> <p>Muoio B, Albano D, ..., Annunziata S, Treglia G. The role of [18F]FDG PET/CT in paraneoplastic autoimmune disorders: an umbrella review. <i>Q J Nucl Med Mol Imaging</i>. 2022 Sep;66(3):229-233.</p> <p>Nardone V, Annunziata S, Desideri I, et al. Delta radiomics: a systematic review. <i>Radiol Med</i>. 2021 Dec;126(12):1571-1583.</p> <p>Rizzo A, Annunziata S, Salvatori M. Side effects of theragnostic agents currently employed in clinical practice. <i>QJNMI</i>. 2021 Dec 9.</p> <p>Lococo F, Chiappetta M, Annunziata S, et al. Current Roles of PET/CT in Thymic Epithelial Tumours: Which Evidences and Which Prospects? A Pictorial Review. <i>Cancers</i> (Basel). 2021 Dec 3;13(23):6091.</p> <p>Treglia G, Sadeghi R, Annunziata S, et al. PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses. <i>Cancers</i>. 2021; 13(20):5172.</p> <p>Laudicella, R.; Albano, D.; Annunziata, S. et al Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications. <i>Cancers</i> 2019, 11, 1412.</p> <p>Alongi P, Laudicella R, Annunziata S et al. Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 1. <i>Crit Rev Oncol Hematol</i>. 25 Jan 2019</p> <p>Fiorentino A, Laudicella R, Annunziata S, et al. Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2. <i>Crit Rev Oncol Hematol</i>. 2019 Mar 20.</p> <p>Treglia G, Annunziata S, Muoio B, et al. The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: an overview. <i>Int J Endocrinol</i>. 2013;2013:856189.</p>
Case reports	<p>Annunziata S, Rea S, et al. Thrombosis of the Iliac Vein Detected by 64Cu-Prostate-Specific Membrane Antigen (PSMA) PET/CT. <i>Clin Nucl Med</i>. 2021 Jan;46(1):e29-e30</p> <p>Annunziata S, Annovazzi A, Pasqualoni R et al. A rare case of solitary pituitary metastasis from spitzoid melanoma detected by FDG-PET/CT. <i>Clin Nucl Med</i>. 2020 Sep;45(9):725-726.</p> <p>Annunziata S, Cuccaro A, Rizzo A, et al. Bronchial Mucosa-Associated Lymphoid Tissue Lymphoma Staged by 11C-Methionine. <i>Clin Nucl Med</i>. 2018 Aug;43(8):e276-e277</p> <p>Annunziata S, Cuccaro A, Hohaus S. 11C-Methionine-Avid Plasmablastic Lymphoma. <i>Clin Nucl Med</i>. 2017 Nov;42(11):872-873.</p> <p>Annunziata S. A rare case of 18F-FDG avid cardiac synovial sarcoma. <i>Rev Esp Med Nucl Imagen Mol</i>. 2018 Sep - Oct;37(5):322</p> <p>Annunziata S, Cuccaro A, Hohaus S. Dural MALT lymphoma detected by 11C-Methionine PET/CT. <i>Clin Nucl Med</i>. 2017 Dec;42(12):962-963.</p> <p>Annunziata S, Caldarella C. A rare case of dorsal-cervical spine myeloid sarcoma detected on 18F-FDG PET/CT. <i>Rev Esp Med Nucl Imagen Mol</i>. 2017 Mar- Apr;36(2):127-128.</p> <p>Caldarella C, Annunziata S, Rufini V. Improved detection of minimal residual disease by Carbon-11-Methionine PET/CT in a young patient with unusual extramedullary presentation of recurrent multiple myeloma. <i>Clin Nucl Med Clin Nucl Med</i>. 2017;42(2):e130-e134</p> <p>Rizzo A, Zagaria L, Annunziata S, et al. Accumulation of 131I in Esophageal Diverticulum Diagnosed by SPECT/CT. <i>Clin Nucl Med</i>. 2018 Aug 31</p>
Commentaries	<p>Annunziata S, Treglia G. Editorial: Radiomics and artificial intelligence in radiology and nuclear medicine. <i>Front Med</i> (Lausanne). 2023 May 23;10:1216434.</p> <p>Annunziata S, Treglia G, Jamar F et al. Nuclear medicine practice in the field of infection and inflammation imaging: a pragmatcal survey. <i>Eur J Nucl Med</i>. 2022 Feb 17.</p> <p>Annunziata S, Panagiotidis E. Hybrid positron emission tomography/magnetic resonance imaging in musculoskeletal conditions: be hybrid! <i>Q J Nucl Med Mol Imaging</i>. 2022 Mar;66(1):1-2.</p> <p>Annunziata S, Giordano A. Nuclear medicine and immunotherapy: many questions but not many answers yet. <i>Clin Transl Imaging</i> 7, 3–5 (2019).</p> <p>Annunziata S, Calcagni ML, Indovina L, Rufini V. Measurement uncertainty and clinical impact of rPET and qPET in Hodgkin Lymphoma: reply to Laffon and Marthan. <i>Eur J Nucl Med Mol Imaging</i>. 2017 Nov;44(12):2140-2141.</p>
Protocol	<p>Lococo F, Boldrini L, ..., Annunziata S, ...Tortora G, Valentini V, Boccia S, Margaritora S, Scambia G. Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study. <i>BMC Cancer</i>. 2023 Jun 13;23(1):540.</p>

Editorial activities

Journal Boards/Reviewer

Journal Editorial Boards: PLOS-ONE, Frontiers in Medicine; Diagnostics; Pharmaceuticals, Experimental and Therapeutic Medicine; Precision Cancer Medicine; Journal of Molecular Imaging and Dynamics; Frontiers in Nuclear Medicine
Journal Reviewer: Journal of Nuclear Medicine, European Journal of Nuclear Medicine, Cancers, Clinical and Translational Imaging, BMC, DovePress

Books chapters

Radiopharmaceuticals, A Guide to PET/CT and PET/MRI, Chapter: 18F-Estradiol. ISBN: TBD. Springer 2020 - updated version 2024.
Lymphoma PET Imaging. Chapter: PET Radiomics and AI. ISBN: TBD, Springer 2025, ongoing
Evidence-based Positron Emission Tomography: Summary of Recent Meta-analyses on PET. PET for abdominal and pelvic tumours. ISBN: 978-303047701-1;978-303047700-4. Springer. 2020
Il curriculum nazionale per la Scuola di Specializzazione in Medicina Nucleare. Progetto Pilota dell'Università di Genova per la stesura e implementazione di Competency-Based Curricula nelle Scuole di Specializzazione. ISBN: 978-88-3618-040-0. GUP Genova University Press. 2020
PET tracers in glioma imaging. Gliomas: Classification, Symptoms, Treatment and Prognosis. ISBN: 978-163117875-7; 978-163117868-9. Nova Science. 2014

Roma 21.07.2025

